Invest KOREA

According to Yonhap News,

(SEOUL=Yonhap News) The U.S.-based pharmaceutical company Biogen Inc. has launched a branch in South Korea, industry sources said Sunday, as it takes steps to tap deeper into the local market.

According to the sources, the U.S. firm, which posted US$11.4 billion in sales last year, registered Biogen Korea LLC in South Korea on July 14.

The company established Samsung Bioepis Co. jointly with Samsung Biologics Co., an affiliate of South Korea's No. 1 conglomerate Samsung, in 2012.

Earlier this year, Biogen sought to win approval for the domestic sale of its SPINRAZA, a treatment for spinal muscular atrophy, from South Korea's Ministry of Food and Drug Safety.



colin@yna.co.kr

Copyrights Yonhap News.

All Rights Reserved.